Precision-Guided Therapy Selection

Unpredictable response can make biologic therapies challenging

Anti-TNF biologics have been shown to be highly effective for IBD patients, but the variability in response can make the process for patients to achieve and maintain remission burdensome.

Common factors impacting drug exposure and efficacy:

• Accelerated drug clearance^1-2
• Antidrug antibody development driven by pharmacokinetics and/or genetic predisposition^1-4

Early selection of the right therapeutic and effective management improves patient outcomes

By optimizing the selection and management of the first therapeutic, patients experience:

• Better disease control and an increased likelihood of achieving sustained remission^5-7
• Reduced risk of surgery or hospitalizations, and improved quality of life^5-7

Tools to confidently select an appropriate therapy plan before initiation have been limited — until now.

Pre-therapy clearance and genetic risk can predict a patient’s response to anti-TNFs

Accelerated pre-therapy clearance (>0.326 L/day) and carriage of the HLA-DQA1*05 G allele significantly impact therapy response.¹ Patients with these factors are:

• 2x more likely to develop antidrug antibodies¹
• Less likely to achieve clinical, biochemical or endoscopic remission^1,4,8

Identifying patient risk factors prior to therapy selection enables treatment plans to be personalized to the IBD patient.

Respondr assesses patient pharmacokinetics and genetics to guide therapy selection and optimization

Respondr incorporates pre-therapy clearance and genetic risk to indicate a patient’s likelihood of response to infliximab, adalimumab or their biosimilars — prior to initiation of therapy.